The effect of pravastatin in patients with primary hyperlipidaemia.

M. Mafauzy, M. Mokhtar, W. B. Wan Mohamad, M. Musalmah

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Thirty-four (34) subjects with primary hyperlipidaemia were enrolled for this study. After low fat dietary therapy for 6 weeks, subjects' whose serum total cholesterol fell to below 6.2 mmol/l (11 subjects) were excluded from the study and those whose serum total cholesterol were 6.2 mmol/l or more (23 subjects) were started on pravastatin 10 mg nocte. After 8 weeks of treatment, there was a significant decrease in the mean total cholesterol and LDL-cholesterol. However 13 of the subjects still had serum total cholesterol 6.2 mmol/l or more and their pravastatin dose was increased to 20 mg nocte. After 12 weeks, there was a significant reduction in triglyceride, total cholesterol and LDL-cholesterol. There was also a significant increase in HDL-cholesterol. The triglyceride fell by a mean of 15.7%, total cholesterol by a mean of 18.1% and LDL-cholesterol by a mean of 26.3%. HDL-cholesterol on the other hand, increased by 19.4%. The subjects whose total cholesterol fell below 6.2 mmol/l at week 8 had significantly lower total cholesterol to begin with than those whose total cholesterol failed to do so and hence were commenced on 20 mg pravastatin. This suggests that the optimum dose of the drug is dependent on the initial level of total cholesterol. We conclude that pravastatin is effective as a lipid lowering agent.

Original languageEnglish
Pages (from-to)272-277
Number of pages6
JournalThe Medical journal of Malaysia
Volume50
Issue number3
Publication statusPublished - Sep 1995
Externally publishedYes

Fingerprint

Pravastatin
Hyperlipidemias
Cholesterol
LDL Cholesterol
HDL Cholesterol
Triglycerides
Serum
Dietary Fats
Lipids

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mafauzy, M., Mokhtar, M., Wan Mohamad, W. B., & Musalmah, M. (1995). The effect of pravastatin in patients with primary hyperlipidaemia. The Medical journal of Malaysia, 50(3), 272-277.

The effect of pravastatin in patients with primary hyperlipidaemia. / Mafauzy, M.; Mokhtar, M.; Wan Mohamad, W. B.; Musalmah, M.

In: The Medical journal of Malaysia, Vol. 50, No. 3, 09.1995, p. 272-277.

Research output: Contribution to journalArticle

Mafauzy, M, Mokhtar, M, Wan Mohamad, WB & Musalmah, M 1995, 'The effect of pravastatin in patients with primary hyperlipidaemia.', The Medical journal of Malaysia, vol. 50, no. 3, pp. 272-277.
Mafauzy M, Mokhtar M, Wan Mohamad WB, Musalmah M. The effect of pravastatin in patients with primary hyperlipidaemia. The Medical journal of Malaysia. 1995 Sep;50(3):272-277.
Mafauzy, M. ; Mokhtar, M. ; Wan Mohamad, W. B. ; Musalmah, M. / The effect of pravastatin in patients with primary hyperlipidaemia. In: The Medical journal of Malaysia. 1995 ; Vol. 50, No. 3. pp. 272-277.
@article{cbabab37a38a47b993c333c26a336f0c,
title = "The effect of pravastatin in patients with primary hyperlipidaemia.",
abstract = "Thirty-four (34) subjects with primary hyperlipidaemia were enrolled for this study. After low fat dietary therapy for 6 weeks, subjects' whose serum total cholesterol fell to below 6.2 mmol/l (11 subjects) were excluded from the study and those whose serum total cholesterol were 6.2 mmol/l or more (23 subjects) were started on pravastatin 10 mg nocte. After 8 weeks of treatment, there was a significant decrease in the mean total cholesterol and LDL-cholesterol. However 13 of the subjects still had serum total cholesterol 6.2 mmol/l or more and their pravastatin dose was increased to 20 mg nocte. After 12 weeks, there was a significant reduction in triglyceride, total cholesterol and LDL-cholesterol. There was also a significant increase in HDL-cholesterol. The triglyceride fell by a mean of 15.7{\%}, total cholesterol by a mean of 18.1{\%} and LDL-cholesterol by a mean of 26.3{\%}. HDL-cholesterol on the other hand, increased by 19.4{\%}. The subjects whose total cholesterol fell below 6.2 mmol/l at week 8 had significantly lower total cholesterol to begin with than those whose total cholesterol failed to do so and hence were commenced on 20 mg pravastatin. This suggests that the optimum dose of the drug is dependent on the initial level of total cholesterol. We conclude that pravastatin is effective as a lipid lowering agent.",
author = "M. Mafauzy and M. Mokhtar and {Wan Mohamad}, {W. B.} and M. Musalmah",
year = "1995",
month = "9",
language = "English",
volume = "50",
pages = "272--277",
journal = "Medical Journal of Malaysia",
issn = "0300-5283",
publisher = "Malaysian Medical Association",
number = "3",

}

TY - JOUR

T1 - The effect of pravastatin in patients with primary hyperlipidaemia.

AU - Mafauzy, M.

AU - Mokhtar, M.

AU - Wan Mohamad, W. B.

AU - Musalmah, M.

PY - 1995/9

Y1 - 1995/9

N2 - Thirty-four (34) subjects with primary hyperlipidaemia were enrolled for this study. After low fat dietary therapy for 6 weeks, subjects' whose serum total cholesterol fell to below 6.2 mmol/l (11 subjects) were excluded from the study and those whose serum total cholesterol were 6.2 mmol/l or more (23 subjects) were started on pravastatin 10 mg nocte. After 8 weeks of treatment, there was a significant decrease in the mean total cholesterol and LDL-cholesterol. However 13 of the subjects still had serum total cholesterol 6.2 mmol/l or more and their pravastatin dose was increased to 20 mg nocte. After 12 weeks, there was a significant reduction in triglyceride, total cholesterol and LDL-cholesterol. There was also a significant increase in HDL-cholesterol. The triglyceride fell by a mean of 15.7%, total cholesterol by a mean of 18.1% and LDL-cholesterol by a mean of 26.3%. HDL-cholesterol on the other hand, increased by 19.4%. The subjects whose total cholesterol fell below 6.2 mmol/l at week 8 had significantly lower total cholesterol to begin with than those whose total cholesterol failed to do so and hence were commenced on 20 mg pravastatin. This suggests that the optimum dose of the drug is dependent on the initial level of total cholesterol. We conclude that pravastatin is effective as a lipid lowering agent.

AB - Thirty-four (34) subjects with primary hyperlipidaemia were enrolled for this study. After low fat dietary therapy for 6 weeks, subjects' whose serum total cholesterol fell to below 6.2 mmol/l (11 subjects) were excluded from the study and those whose serum total cholesterol were 6.2 mmol/l or more (23 subjects) were started on pravastatin 10 mg nocte. After 8 weeks of treatment, there was a significant decrease in the mean total cholesterol and LDL-cholesterol. However 13 of the subjects still had serum total cholesterol 6.2 mmol/l or more and their pravastatin dose was increased to 20 mg nocte. After 12 weeks, there was a significant reduction in triglyceride, total cholesterol and LDL-cholesterol. There was also a significant increase in HDL-cholesterol. The triglyceride fell by a mean of 15.7%, total cholesterol by a mean of 18.1% and LDL-cholesterol by a mean of 26.3%. HDL-cholesterol on the other hand, increased by 19.4%. The subjects whose total cholesterol fell below 6.2 mmol/l at week 8 had significantly lower total cholesterol to begin with than those whose total cholesterol failed to do so and hence were commenced on 20 mg pravastatin. This suggests that the optimum dose of the drug is dependent on the initial level of total cholesterol. We conclude that pravastatin is effective as a lipid lowering agent.

UR - http://www.scopus.com/inward/record.url?scp=0029364839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029364839&partnerID=8YFLogxK

M3 - Article

C2 - 8926908

AN - SCOPUS:0029364839

VL - 50

SP - 272

EP - 277

JO - Medical Journal of Malaysia

JF - Medical Journal of Malaysia

SN - 0300-5283

IS - 3

ER -